Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28537559 | 1.00 | GPR119 (0.46) | GPR119KMT2AMEN1MMP13TP53 | |
| SCHEMBL28537557 | 1.00 | GPR119 (0.46) | GPR119KMT2AMEN1MMP13TP53 | |
| SCHEMBL21552586 | 0.88 | ALDH1A1 (0.34) | KMT2A | |
| SCHEMBL21552625 | 0.88 | ALDH1A1 (0.34) | KMT2A | |
| SCHEMBL23364110 | 0.88 | ALDH1A1 (0.34) | KMT2A | |
| SCHEMBL29785044 | 0.82 | STS (0.46) | GPR119 | |
| SCHEMBL28837017 | 0.82 | GPR119 (0.46) | GPR119KMT2AMEN1MMP13TP53 | |
| SCHEMBL28837015 | 0.82 | GPR119 (0.46) | GPR119KMT2AMEN1MMP13TP53 | |
| SCHEMBL29770088 | 0.82 | HTR7 (0.52) | GPR119KMT2AMEN1 | |
| SCHEMBL21552576 | 0.81 | CA12 (0.38) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070908-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070907-A1 | FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | UNIV TEMPLE (US) | 2026-03-12 | — | — | US | disclosed |
| US-12559494-B2 | Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-02-24 | — | — | US | disclosed |
| CN-112437768-B | Novel functionalized lactams as modulators of 5-hydroxytryptamine receptor 7 and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2025-06-24 | — | — | CN | disclosed |
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2023-01-05 | — | — | US | disclosed |
| US-20220306629-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | PRAEVENTIX, LLC | 2022-09-29 | — | — | US | disclosed |
| EP-4058455-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | Temple University - Of The Commonwealth System of Higher Education (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-115003675-A | Novel functionalized lactams as 5-hydroxytryptamine receptor 7 modulators and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2022-09-02 | — | — | CN | disclosed |
| CN-112437768-A | Novel functionalized lactams as 5-hydroxytryptamine receptor 7 modulators and methods of use thereof | 英联邦高等教育系统坦普尔大学 | 2021-03-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559494-B2 | Functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use | HTR1B, HTR7, HTR6 | GPR119 912/4885KMT2A 3250/4885MEN1 3743/4885 |
| US-20260070907-A1 | FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, HTR5A | GPR119 295/4885KMT2A 2348/4885MEN1 2505/4885 |
| US-20260070908-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR2C, TPH2 | GPR119 181/4885KMT2A 1855/4885MEN1 3067/4885 |
| US-20220306629-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR5A, HTR1A | GPR119 185/4885KMT2A 3467/4885MEN1 2359/4885 |
| US-20230002383-A1 | NOVEL FUNCTIONALIZED LACTAMS AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR 7 AND THEIR METHOD OF USE | HTR7, HTR1A, HTR2C | GPR119 234/4885KMT2A 4293/4885MEN1 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.